[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,026,116
  • Shares Outstanding, K 64,526
  • Annual Sales, $ 184,420 K
  • Annual Income, $ -6,890 K
  • EBIT $ -223 M
  • EBITDA $ -223 M
  • 60-Month Beta 1.20
  • Price/Sales 11.56
  • Price/Cash Flow N/A
  • Price/Book 6.17

Options Overview Details

View History
  • Implied Volatility 57.41% (-13.72%)
  • Historical Volatility 47.05%
  • IV Percentile 1%
  • IV Rank 11.79%
  • IV High 135.55% on 11/19/25
  • IV Low 46.96% on 05/21/26
  • Expected Move (DTE 27) 0.98 (3.03%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 33
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 3.18
  • Today's Open Interest 3,631
  • Open Int (30-Day) 3,199
  • Expected Range 31.31 to 33.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.87
  • Number of Estimates 3
  • High Estimate $-0.80
  • Low Estimate $-0.99
  • Prior Year $-0.65
  • Growth Rate Est. (year over year) -33.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.96 +15.49%
on 07/22/26
33.56 -3.77%
on 08/12/26
+3.48 (+12.08%)
since 07/21/26
3-Month
27.24 +18.56%
on 07/21/26
33.72 -4.24%
on 07/07/26
+2.62 (+8.83%)
since 05/21/26
52-Week
18.00 +79.39%
on 08/26/25
40.22 -19.72%
on 03/10/26
+12.61 (+64.08%)
since 08/21/25

Most Recent Stories

More News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.29 (+2.83%)
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 – – Pre-NDA...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Prepares to Defend Its Pipeline Narrative, But Zorevunersen Data Timing Looms Large

Barchart Research What to Expect from STOK Earnings STOK Generated July 31, 2026 Current Price $28.86 EPS Estimate $$-0.82 Consensus Rating Strong Buy Average Move 6.33% Stoke Therapeutics Prepares to...

STOK : 32.29 (+2.83%)
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.29 (+2.83%)
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases–

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.29 (+2.83%)
Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 34.11
2nd Resistance Point 33.44
1st Resistance Point 32.86
Last Price 32.29
1st Support Level 31.62
2nd Support Level 30.95
3rd Support Level 30.37

See More

52-Week High 40.22
Last Price 32.29
Fibonacci 61.8% 31.73
Fibonacci 50% 29.11
Fibonacci 38.2% 26.49
52-Week Low 18.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.